Talis One STI Panel

About Talis Biomedical

Talis Biomedical was founded to commercialize the Talis One platform, a compact, cartridge-based molecular diagnostic system designed for decentralized testing. The company achieved a public listing via a SPAC merger in 2021 but faced insurmountable hurdles in scaling manufacturing and adapting to the post-pandemic market, leading to a strategic wind-down. Its current strategy is solely focused on liquidating assets and seeking a sale or merger of its remaining technology and intellectual property.

Therapeutic Areas